The impact of depression extends beyond the individual, affecting our communities daily. Major depressive disorder stands as the leading global cause of disability and carries significant implications for the economy, businesses, and families. In the United States, over $30 billion is spent annually on treatments for major depressive disorder. 

For those grappling with depression, it can feel like an endless struggle, especially as most first-line therapies often fall short. Without a dependable method to gauge medication effectiveness, providers resort to a trial-and-error approach, prescribing medications and waiting to observe their patients’ responses. At Circular Genomics, we are eliminating this sub-optimal standard of care with a biomarker-based approach to psychiatric treatment.